Takeda MDD 318
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor–Induced Sexual Dysfunction.
| Protocol | Lu AA21004_318 |
|---|
| Identifier | Lu AA21004_318 Site Number 5028 |
|---|
| UID | eee8877e-7db1-4a8b-be0b-2a16bb976cd8 |
|---|
| Status | Done - Archived |
|---|
| Phase | 3b |
|---|
| Category | Major Depressive Disorder / Adult |
|---|
| Launch Year | 2011 |
|---|
| NCT Number | - |
|---|
| Created | 2011-06-13 17:00 |
|---|
| Last Updated | 2011-06-13 17:00 |
|---|
Description
Key Elements: Study drug LuAA21004 is being compared to Escitalopram (Lexaori), Approximately 13 weeks (8 visits). $45 compensation per visit. Study drug administration: 1 tablet per day, morning, with or without food. Subject will discontinue their current SSRI at Visit 2 and for the study duration. Due to the fact the sexual dysfunction must be attributable to the SSRI use, per Dr. Mohaupt, we prefer subjects who are on not other concomitant medications and/or illnesses. However, Team Alpha can review on a case by case basis if the subject is otherwise eligible.
Comment
No comment.
